Earnings Recaps

Browse reported earnings of the most popular stocks

Nov 13, 2026 Nov 12, 2026 Nov 11, 2026 Nov 10, 2026 Nov 9, 2026 Nov 8, 2026 Nov 7, 2026 Nov 6, 2026 Nov 5, 2026 Nov 4, 2026 Nov 3, 2026 Nov 2, 2026 Nov 1, 2026 Oct 31, 2026 Oct 30, 2026 Oct 29, 2026 Oct 28, 2026 Oct 27, 2026 Oct 26, 2026 Oct 25, 2026 Oct 24, 2026 Oct 23, 2026 Oct 22, 2026 Oct 21, 2026 Oct 20, 2026 Oct 19, 2026 Oct 18, 2026 Oct 17, 2026 Oct 16, 2026 Oct 15, 2026 Oct 14, 2026 Oct 13, 2026 Oct 11, 2026 Oct 10, 2026 Oct 9, 2026 Oct 8, 2026 Oct 7, 2026 Oct 3, 2026 Oct 2, 2026 Oct 1, 2026 Sep 30, 2026 Sep 29, 2026 Sep 27, 2026 Sep 26, 2026 Sep 25, 2026 Sep 24, 2026 Sep 23, 2026 Sep 19, 2026 Sep 18, 2026 Sep 17, 2026 Sep 16, 2026 Sep 14, 2026 Sep 13, 2026 Sep 12, 2026 Sep 11, 2026 Sep 10, 2026 Sep 9, 2026 Sep 8, 2026 Sep 5, 2026 Sep 4, 2026 Sep 3, 2026 Sep 2, 2026 Sep 1, 2026 Aug 31, 2026 Aug 30, 2026 Aug 29, 2026 Aug 28, 2026 Aug 27, 2026 Aug 26, 2026 Aug 25, 2026 Aug 23, 2026 Aug 22, 2026 Aug 21, 2026 Aug 20, 2026 Aug 19, 2026 Aug 18, 2026 Aug 17, 2026 Aug 16, 2026 Aug 15, 2026 Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026
72 companies Today

Applied Optoelectronics, Inc.

AAOI Q3 2026
Reported: 2026-11-08

AOI’s shares rose 6.9% after earnings, with investors likely rewarding record revenue, rapidly growing 800G sales and a multiyear 1.6T agreement with a Tier 1 hyperscaler. The quarter was not an across-the-board beat: gross margin came in below the company’s guidance range, and a construction delay pushes back its capacity expansion.

Key takeaways
  • Q3 revenue was a record $269.9 million, more than double year over year and within the company’s $255 million–$290 million guidance range.
  • Non-GAAP gross margin was 28.7%, below the 29%–30.5% guidance range due to product mix; non-GAAP diluted EPS of $0.17 was within guidance of $0.11–$0.26.
  • 800G revenue nearly quadrupled sequentially to $47.5 million, while 400G revenue nearly doubled sequentially. The new multiyear agreement with a Tier 1 hyperscaler is entirely for 1.6T transceivers.
  • Phase I at the new Sugar Land facility is set to begin operating in December, but Phase II is expected to be delayed by several months, partly because of longer-than-expected electrical-power timelines.
  • Management said the delay shifts its target of reaching a $471 million monthly revenue run rate toward the end of 2027; it expects a significant revenue ramp in Q4 and the following quarters.

Koninklijke Ahold Delhaize N.V.

AD.AS Q3 2026
Reported: 2026-11-08

Ahold Delhaize shares rose 7.7% after earnings, with the quarter’s positive volume growth, market-share gains and maintained profitability supporting the result. The key caveat is that the October cybersecurity incident disrupted online operations and parts of the Benelux supply chain, and management said it will affect Q4 performance.

Key takeaways
  • The company reported positive volume growth in both regions and market-share gains across its key markets, while maintaining what management called healthy profitability.
  • Own-brand penetration increased 50 basis points year-to-date; in Europe, own brand represents half of food sales.
  • U.S. brands delivered more than 4.3 billion personalized offers during the quarter. Omnichannel customers spend, on average, 1.5x to 3x as much as customers shopping only in physical stores.
  • The October cybersecurity incident affected online capabilities in the Benelux and U.S., as well as parts of the Benelux supply chain; bol was not affected. The investigation is ongoing.

ADMA Biologics, Inc.

ADMA Q3 2026
Reported: 2026-11-08

ADMA shares rose 26.0% after earnings, as investors responded to 31% year-over-year ASCENIV growth, 71% corporate gross margin and substantial earnings growth. The quarter also showed continued pressure on BIVIGAM revenue, while management pointed to early signs of stabilization in end-user utilization.

Key takeaways
  • ASCENIV revenue was $124.7 million, up 31% year over year and 21% sequentially; management cited broader physician adoption, new patient starts and higher end-user utilization.
  • Total revenue increased 13% sequentially to $141.1 million, and corporate gross margin was 71%.
  • BIVIGAM revenue fell to $15.4 million from $19.4 million in the second quarter amid pricing and competitive pressure; management said underlying utilization showed signs of stabilization entering the fourth quarter.
  • ADMA repurchased 16.5 million shares through September 30, about 6.3% of shares outstanding at year-end 2025, and remained on track for its target of at least $200 million in 2026 repurchases.
  • Management said ASCENIV growth in secondary immunodeficiency patients has been moderate so far, despite viewing that population as a potential additional growth opportunity.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...